Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Gliomas, particularly glioblastoma, are aggressive brain tumors known for resistance to conventional therapies.
• Endogenous nitric oxide (NO) is implicated in treatment resistance.
• 5-aminolevulinic acid (ALA)-based photodynamic therapy (PDT) shows promise for glioblastoma treatment.

Purpose of the Study:

• To investigate the role of nitric oxide (NO) produced by glioblastoma cells in interfering with ALA-based photodynamic therapy (PDT).
• To assess the impact of NO on glioblastoma cell apoptosis, proliferation, migration, and invasion following ALA-PDT.

Main Methods:

• Utilized an in vitro model with human U87 and U251 glioblastoma cells.
• Measured neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) levels.
• Assessed apoptosis, proliferation, migration, and invasion rates after ALA/light challenge, with and without iNOS inhibitors or NO scavengers.

Main Results:

• Glioblastoma cells expressed significant basal levels of nNOS and iNOS.
• ALA/light challenge increased iNOS levels and intracellular NO, demonstrating a cytoprotective effect.
• Inhibition of iNOS or NO scavenging significantly enhanced ALA/light-induced apoptosis.
• Surviving cells showed increased proliferation, migration, and invasion, mediated by iNOS/NO, matrix metalloproteinase-9, and survivin.

Conclusions:

• Inducible nitric oxide synthase (iNOS) and its product NO play a cytoprotective role in glioblastoma cells during ALA-PDT.
• iNOS/NO signaling promotes glioblastoma cell survival, proliferation, invasion, and potentially metastasis.
• Inhibitors of iNOS could serve as effective pharmacologic adjuvants to improve glioblastoma PDT outcomes.